CSIMarket Company Name, Ticker, Suppliers, else..
 
Immuron Limited  (NASDAQ: IMRN)
Other Ticker:  
 
 
Price: $2.0000 $-0.05 -2.439%
Day's High: $2.12 Week Perf: -6.98 %
Day's Low: $ 2.00 30 Day Perf: 2.04 %
Volume (M): 8 52 Wk High: $ 5.96
Volume (M$): $ 16 52 Wk Avg: $2.30
Open: $2.12 52 Wk Low: $1.59



 Market Capitalization (Millions $) 5
 Shares Outstanding (Millions) 2
 Employees 12
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -4
 Cash Flow (TTM) (Millions $) 22
 Capital Exp. (TTM) (Millions $) 0

Immuron Limited
Immuron Limited is a biopharmaceutical company that develops and commercializes oral immunotherapeutics for the treatment and/or prevention of various diseases and infections. The company's products are designed to target and improve the gut microbiome, which plays a crucial role in maintaining overall health. Immuron's lead product, Travelan, is a travel vaccine that helps prevent and treat travelers' diarrhea caused by E. coli and other bacteria. Additionally, the company is also involved in developing other immunotherapeutic products for the treatment of C. difficile infection, non-alcoholic steatohepatitis (NASH), and liver diseases. Immuron Limited is headquartered in Melbourne, Australia, and works to advance its products through clinical trials and commercialization partnerships.


   Company Address: Level 3, 62 Lygon Street Victoria 3053
   Company Phone Number: 3 9822 7735   Stock Exchange / Ticker: NASDAQ IMRN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV      % 
ABT      % 
BMY      % 
JNJ      % 
MRK      % 
PFE      % 
• View Complete Report
   



Product Service News

Immurons Travelan Sales Surge Amidst Financial Hurdles,

Published Tue, Oct 15 2024 10:00 AM UTC

Immuron Limited Reports Sustained Sales Momentum for Travelan amidst Financial Challenges MELBOURNE, Australia, Oct. 15, 2024 Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian-based and globally integrated biopharmaceutical company, proudly announced the continued strong sales growth of its over-the-counter immune supplement, Travelan. Designed to combat pathogenic b...
Clinical Study

Navigating the Path to Gut Health Emerging Therapies Targeting Campylobacter and ETEC

Published Fri, Oct 4 2024 10:30 AM UTC

In recent developments that underscore the intersection of innovation and global health challenges, Immuron Limited, an Australian biopharmaceutical company, has announced positive interim results following their collaboration with the US Naval Medical Research Command (NMRC) regarding a new oral therapeutic candidate aimed at infections caused by Campylobacter and Enterotox...
Management Announcement

Immuron Files Pre-IND Application with FDA for IMM-529, Stocks Surge 17.82% in Five Trading Days.

Published Tue, Jul 2 2024 10:00 AM UTC

Immuron Requests Pre-IND Meeting with FDA for IMM-529 and Shares Soar 17.82% in Five Trading Days
Melbourne, Australia - Immuron Limited (ASX: IMC; NASDAQ: IMRN), a leading global biopharmaceutical company based in Australia, is excited to announce the submission of a pre-IND (investigational new drug) application to the United States Food and Drug Administration (FDA) f...
Immuron Limited

Immuron Limited reports decreased revenue and widened net loss in Q4 2023



In the financial fourth quarter of 2023, Immuron Limited, a major pharmaceutical preparations company, reported its financial results, which revealed a decrease in revenue and widened net loss. These figures mark a notable change compared to the corresponding financial reporting period from the previous year. This article aims to examine the context behind Immuron Limited's financial results, including its stock performance and implications for investors.
Financial Results:
Immuron Limited disclosed a revenue of $1.480365 million in the financial fourth quarter of 2023 after experiencing a net loss of $-3.787 million. These figures signify a departure from balanced books in the corresponding period a year earlier. Additionally, in the financial year 2023, the company announced a loss of $-3.79 million alongside a revenue of $1.48 million. In comparison to the prior financial year, the net loss per share has widened from $-1.25 to $-1.66, indicating a financial decline. However, it is important to note that the net loss remained unchanged from $0.00 million a year earlier.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com